We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) introduced novel magnet technology and analytical solutions at the 65th ENC. The novel technology facilitates the widespread application of NMR in academic basic and clinical research, as well as in drug discovery and development by biopharmacies and process analytical technologies (PAT).
The latest development will fortify Bruker’s Scientific Instruments (BSI) BioSpin segment.
More on New Magnet Technology
At the 65th ENC, with a complete one-year liquid helium hold-time, more than doubling refill intervals, Bruker presents the Ascend Evo 600, a unique compact 54 mm standard-bore 14.1 Tesla (600 MHz) NMR magnet. In comparison with earlier 600 MHz magnets, the new Ascend Evo 600 magnet requires less helium, is simpler to site and has lower installation and operating expenses.
Moreover, Bruker broadens the range of uses for its Fourier 80 platform — a tabletop 80 MHz Fourier Transform NMR equipped with a powerful permanent magnet that doesn't require cryogens or electricity. To synchronize with sensors and other analytical methods, such as infrared or Raman spectroscopy, the Fourier 80 can be integrated with synTQTM PAT management software. This allows for numerous integrated data streams that offer more thorough process analysis and quality control.
Benefits of New Technology Introduction
Advanced characterization of biologics and new drug modalities are made possible by Bruker's Ascend Evo series, which makes NMR more accessible to researchers in a variety of domains, including clinical metabolism research and the biopharma business.
In lab or industrial environments, the Fourier PAT solution offers a plethora of structural information, selectivity, and immediate quantification, which minimizes laborious calibrations and improves (bio)process control.
Image Source: Zacks Investment Research
Active pharmaceutical ingredients (APIs) can be manufactured in a distributed manner using the Fourier PAT solution. Here, the Fourier 80 system collects response data so that AI machine learning may create the guidelines and directives that direct the optimization of processes.
This PAT setup is game-changing in the way APIs get produced, enabling distributed manufacturing and on-demand production. Coupling the PAT module with an AI agent in the API manufacturing unit enhances the advantages that accompany flow chemistry, such as increased safety, reduced environmental footprint and better economics.
Industry Prospects
Per the Grand View Research report, the global nuclear magnetic resonance spectroscopy market size was valued at $690 million in 2022 and is expected to witness a CAGR of 5.1% from 2023 to 2030. The upside of NMR spectroscopy is supported by universities, product developers and service providers of pharmaceutical companies.
Progress within NMR capabilities
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life by encouraging innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI.
In December 2023, Bruker installed a 1.2 Gigahertz (GHz) nuclear magnetic resonance (NMR) system at the National Gateway Ultrahigh Field NMR Center at Ohio State University. The installation of the 1.2 GHz NMR device enables the investigation of the structure and dynamics of biological molecules in unprecedented detail. This breakthrough will allow researchers to make major gains in understanding how these molecules work, ultimately leading to the creation of new disease treatments.
Price Performance
In the past year, BRKR’s shares have gained 14.3% against the industry’s fall of 6.8%.
Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Stryker Corporation (SYK - Free Report) , Cencora, Inc. (COR - Free Report) and Cardinal Health (CAH - Free Report) .
Stryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Cencora, carrying a Zacks Rank #2, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.
Cardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
Bruker Corporation (BRKR - Free Report) introduced novel magnet technology and analytical solutions at the 65th ENC. The novel technology facilitates the widespread application of NMR in academic basic and clinical research, as well as in drug discovery and development by biopharmacies and process analytical technologies (PAT).
The latest development will fortify Bruker’s Scientific Instruments (BSI) BioSpin segment.
More on New Magnet Technology
At the 65th ENC, with a complete one-year liquid helium hold-time, more than doubling refill intervals, Bruker presents the Ascend Evo 600, a unique compact 54 mm standard-bore 14.1 Tesla (600 MHz) NMR magnet. In comparison with earlier 600 MHz magnets, the new Ascend Evo 600 magnet requires less helium, is simpler to site and has lower installation and operating expenses.
Moreover, Bruker broadens the range of uses for its Fourier 80 platform — a tabletop 80 MHz Fourier Transform NMR equipped with a powerful permanent magnet that doesn't require cryogens or electricity. To synchronize with sensors and other analytical methods, such as infrared or Raman spectroscopy, the Fourier 80 can be integrated with synTQTM PAT management software. This allows for numerous integrated data streams that offer more thorough process analysis and quality control.
Benefits of New Technology Introduction
Advanced characterization of biologics and new drug modalities are made possible by Bruker's Ascend Evo series, which makes NMR more accessible to researchers in a variety of domains, including clinical metabolism research and the biopharma business.
In lab or industrial environments, the Fourier PAT solution offers a plethora of structural information, selectivity, and immediate quantification, which minimizes laborious calibrations and improves (bio)process control.
Image Source: Zacks Investment Research
Active pharmaceutical ingredients (APIs) can be manufactured in a distributed manner using the Fourier PAT solution. Here, the Fourier 80 system collects response data so that AI machine learning may create the guidelines and directives that direct the optimization of processes.
This PAT setup is game-changing in the way APIs get produced, enabling distributed manufacturing and on-demand production. Coupling the PAT module with an AI agent in the API manufacturing unit enhances the advantages that accompany flow chemistry, such as increased safety, reduced environmental footprint and better economics.
Industry Prospects
Per the Grand View Research report, the global nuclear magnetic resonance spectroscopy market size was valued at $690 million in 2022 and is expected to witness a CAGR of 5.1% from 2023 to 2030. The upside of NMR spectroscopy is supported by universities, product developers and service providers of pharmaceutical companies.
Progress within NMR capabilities
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life by encouraging innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI.
In December 2023, Bruker installed a 1.2 Gigahertz (GHz) nuclear magnetic resonance (NMR) system at the National Gateway Ultrahigh Field NMR Center at Ohio State University. The installation of the 1.2 GHz NMR device enables the investigation of the structure and dynamics of biological molecules in unprecedented detail. This breakthrough will allow researchers to make major gains in understanding how these molecules work, ultimately leading to the creation of new disease treatments.
Price Performance
In the past year, BRKR’s shares have gained 14.3% against the industry’s fall of 6.8%.
Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Stryker Corporation (SYK - Free Report) , Cencora, Inc. (COR - Free Report) and Cardinal Health (CAH - Free Report) .
Stryker, carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Cencora, carrying a Zacks Rank #2, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.
Cardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.